EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Myeloid cell path to malignancy: insights into liver cancer

Christel F A Ramirez, Leila Akkari

Trends in Cancer · 2025

DOI: 10.1016/j.trecan.2025.02.006 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2025. Verfasst von Christel F A Ramirez und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Tumor Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Myeloid Cells. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: KWF Kankerbestrijding, Ministerie van Volksgezondheid, Welzijn en Sport, Cancer Genomics Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinically approved treatments for advanced liver cancer often lack potency because of the heterogeneous characteristics of hepatocellular carcinoma (HCC). This complexity is largely driven by context-dependent inflammatory responses brought on by diverse etiologies, such as metabolic dysfunction-associated steatohepatitis (MASH), the genetic makeup of cancer cells, and the versatile adaptability of immune cells, such as myeloid cells. In this review, we discuss the evolutionary dynamics of the immune landscape, particularly that of liver-resident Kupffer cells (KCs), TREM2+, and SPP1+ macrophages with an active role during liver disease progression, which eventually fuels hepatocarcinogenesis. We highlight exploitable immunomodulatory avenues amenable to mitigate both the inherent pathological characteristics of liver cancers and the associated external factors that favor malignancy, paving a roadmap toward improving the management and therapeutic outcome for patients with HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularMyeloid CellsHumansKupffer CellsTumor MicroenvironmentAnimalsDisease ProgressionLiverReceptors, ImmunologicMacrophagesMembrane Glycoproteins

Stichwörter der Autor:innen

cancer cell geneticsliver cancermacrophagesmetabolic dysfunction-associated steatohepatitis (MASH)secreted phosphoprotein 1 (SPP1)triggering receptor expressed on myeloid cells 2 (TREM2)

Substanzen

Receptors, ImmunologicTREM2 protein, humanMembrane Glycoproteins

Autor:innen und Institutionen

  • Division of Tumor Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
  • Division of Tumor Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Electronic address: l.akkari@nki.nl.

Förderung

  • KWF Kankerbestrijding
  • Ministerie van Volksgezondheid, Welzijn en Sport
  • Cancer Genomics Centre
  • Oncode Institute

Zitieren

APA

Ramirez, C. F. A., & Akkari, L. (2025). Myeloid cell path to malignancy: insights into liver cancer. Trends in Cancer. https://doi.org/10.1016/j.trecan.2025.02.006

Vancouver

Ramirez CFA, Akkari L. Myeloid cell path to malignancy: insights into liver cancer. Trends in Cancer. 2025. doi:10.1016/j.trecan.2025.02.006

BibTeX
@article{Ramirez2025,
  author = {Ramirez, Christel F A and Akkari, Leila},
  title = {Myeloid cell path to malignancy: insights into liver cancer},
  journal = {Trends in Cancer},
  year = {2025},
  doi = {10.1016/j.trecan.2025.02.006}
}
Kostenlos starten →